The health system is partnering with pharmaceutical company Eisai to study the value of an algorithm, known as a Passive Digital Marker, on a set of de-identified data to identify individuals dealing with cognitive impairment, which may suggest early signs of dementia, according to an April 4 press release.
“As we continue to develop new treatments to prevent and slow the progression of Alzheimer’s and related dementias, early detection is becoming even more important,” said Glen Finney, MD, director of Geisinger’s Memory and Cognition Program. “Early and accurate diagnosis and treatment of these conditions can drastically improve outcomes and quality of life for both patients and caregivers.”
The AI technology aims to better understand the root causes of dementia and other neurological conditions, to aid in better treatments and early detection.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
